IMMULOGIC Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMULOGIC

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jeffers Hughes who wrote (118)	2/11/1997 2:53:00 AM
From: Rick Strange	of 305

4th Qtr & FY96 Earnings. IMUL reported 4th. Qtr. earnings of ($0.01) vs. ($0.31) in 95. FY96 of ($0.93) vs FY95 of ($1.12) 4th. Qtr. results included a one-time $7 million payment from Hoechst Marion Roussel resolving their outstanding obligations relating to the joint collaboration on ALLERVAX agreement. "In the first half of 1997 our clinical development program will increase in activity with the planned initiation of an ALLERVAX CAT catroom trial, a multiple sclerosis phase I trial, the filling of an IND and initiation of a phase I trial for cocaine vaccine, and an ALLERVAX RAGWEED trial to be initiated in JUly prior to the start of the next ragweed season" said Joseph Marr, M.D. acting president and chief executive officer of ImmuLogic. IMUL ended 96 with $54.6 million cash and cash equivalents. Rick Strange

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next